series-b
Stage
About
Clarametyx develops immune-enabling biologic therapies targeting bacterial biofilms to treat chronic respiratory diseases and is currently conducting clinical trials for its lead candidate CMTX-101.
Explore Clarametyx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.